Tarek Assi
Overview
Explore the profile of Tarek Assi including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
109
Citations
601
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Assi T, Moussa T, Ngo C, Faron M, Verret B, Levy A, et al.
Cancer Treat Rev
. 2025 Feb;
134:102904.
PMID: 40020639
Tenosynovial giant cell tumor is a non-malignant primary locally aggressive articular disease that affects the synovium of joints, tendon sheaths, and bursae. It is characterized by a translocation t (1;2),...
2.
3.
Ammari S, Camez A, Ayobi A, Quenet S, Zemmouri A, Mniai E, et al.
Life (Basel)
. 2024 Nov;
14(11).
PMID: 39598146
Introduction: The incidence of venous thromboembolism is estimated to be around 3% of cancer patients. However, a majority of incidental pulmonary embolism (iPE) can be overlooked by radiologists in asymptomatic...
4.
Moussa T, Assi T, Kasraoui I, Ammari S, Balleyguier C
Future Oncol
. 2024 Nov;
21(1):1-3.
PMID: 39589757
No abstract available.
5.
Assi T, Hachem M, Amine-Hneineh R, Moussa T
Immunotherapy
. 2024 Nov;
16(20-22):1171-1173.
PMID: 39548753
No abstract available.
6.
Assi T, Tikriti Z, Shayya A, Ibrahim R
Pharmacogenomics
. 2024 Mar;
25(3):113-115.
PMID: 38450459
No abstract available.
7.
McGale J, Howell H, Beddok A, Tordjman M, Sun R, Chen D, et al.
Pharmaceuticals (Basel)
. 2024 Feb;
17(2).
PMID: 38399425
The integration of artificial intelligence (AI) and positron emission tomography (PET) imaging has the potential to become a powerful tool in drug discovery. This review aims to provide an overview...
8.
9.
Khoury R, Assi T, Ibrahim R, Ibrahim T, Verret B, Henon C, et al.
Curr Treat Options Oncol
. 2024 Feb;
25(2):176-190.
PMID: 38324075
Soft tissue sarcoma (STS), a substantial group of aggressive and rare tumors with tissue heterogeneity, is infrequently represented in clinical trials with an urgent necessity for newer treatment options. Lurbinectedin,...
10.
Ibrahim R, Khoury R, Ibrahim T, Cesne A, Assi T
Crit Rev Oncol Hematol
. 2024 Feb;
196:104265.
PMID: 38307394
The use of genetic testing to personalize therapeutic strategies in cancer is rapidly evolving and thus changing the landscape of treatment of oncologic patients. The UGT1A1 gene is an important...